達安基因(002030.SZ):公司實控人由“中山大學”變更為“廣州市人民政府”
格隆匯 12 月 21日丨達安基因(002030.SZ)公佈,2020年12月21日,公司收到廣州中大控股有限公司《關於告知股東變更完成工商變更登記的函》,函件主要內容為:“我公司已於2020年12月18日收到廣州市市場監督管理局《准予變更登記(備案)通知書》,我公司股東由中山大學變更為廣州金融控股集團有限公司,持股比例為100%,法定代表人變更為薛哲強。”
根據控股股東廣州中大控股有限公司最新的工商登記信息,其股東由“中山大學”變更為“廣州金融控股集團有限公司”,導致公司實際控制人由“中山大學”變更為“廣州市人民政府”,公司控股股東不變,仍為中大控股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.